Ankylosing spondylitis
Latest News
Launch of adalimumab biosimilar Amjevita postponed
Amgen reached a deal with AbbVie to settle its patent infringement litigation.
Conference Coverage
Immunogenicity concerns for biosimilars so far don’t go beyond originator biologics
But there are few data available on the impact of antidrug antibodies to biosimilars across rheumatic diseases and on switching.
Conference Coverage
Early ankylosing spondylitis treatment stops transition from inflammatory to bone-forming fatty lesions
“The earlier we treat intensively, the better impact you have on structural outcomes,” according to Dirk Elewaut, MD, PhD.
From the Journals
Ultrasound’s value for arthralgia may be to rule out IA
Ultrasound’s ability to predict the development of inflammatory arthritis was low.
Guidelines
New recommendations tout biosimilars for rheumatologic diseases
An international multidisciplinary task force came up with five overarching principles for the use of biosimilars and eight specific...
News
FDA approves second adalimumab biosimilar for multiple conditions
The biosimilar, called Cyltezo (adalimumab-adbm), is approved for all the same indications as Humira.
From the Journals
Axial SpA features don’t guarantee its diagnosis in chronic back pain
Even when patients with chronic back pain have four or more features of axial spondyloarthritis, a diagnosis of axial spondyloarthritis is not...
From the Journals
Radiographic progression in axial spondyloarthritis moves slowly in first 5 years
The net percentage of patients who progressed was 5%, calculated as those who went from nonradiographic axSpA to radiographic axSpA minus those...
Latest News
First interchangeability study for an adalimumab biosimilar has begun
The trial recently enrolled its first patient.
From the Journals
CT scoring system may improve sacroiliitis treatment in IBD
Sacroiliitis is three times more prevalent among IBD patients and can be reliably detected in CT scans.
Conference Coverage
TNFi treatment halves ankylosing spondylitis progression
Patients on a tumor necrosis factor inhibitor who achieved low disease activity showed virtually no spinal radiographic progression during a 2-...